RecentRCT

ADVOR residual-congestion analysis

Acetazolamide, residual congestion and clinical outcomes in acute heart failure - a prespecified analysis of the ADVOR trial.

Acta cardiologica, 2026 · Prespecified secondary analysis of a randomized trial

Population: 519 parent ADVOR participants
Intervention: IV acetazolamide plus standardized loops
Comparator: Placebo plus loops
Primary outcome: Residual congestion and associations with 90-day death/HF hospitalization
Result: Acetazolamide reduced residual congestion; residual congestion was associated with subsequent events.

What the trial found

Acetazolamide reduced residual congestion; residual congestion was associated with subsequent events.

Clinical interpretation

Parent trial reuse and prognostic association do not demonstrate a new independent survival effect.

Low certainty

Clinical Context & Relevant Topics (2)

Disease Reference

Acute Heart Failure & Cardiogenic Congestion

Hemodynamic phenotypes (SCAPE vs ADHF vs Cardiogenic Shock), non-invasive positive pressure ventilation, high-dose vasodilator algorithms, loop diuretics, and sequential nephron blockade.

View Topic Context →

Acute Cardiogenic Pulmonary Edema & SCAPE

Hydrostatic pulmonary edema physiology, SCAPE vs decompensated HF vs cardiogenic shock, NIV, titrated vasodilators when hypertensive, diuresis, and sequential nephron blockade.

View Topic Context →